Skip to main content

Animations

MJFF Publications

4471 - 4480 of 8818 Results
Title
Year
  • Year
  • 2011
  • 2014
  • 2024
  • 2017
  • 2022
  • 2008
  • 2003
  • 2009
  • 2018
  • 2021
  • Summary Details
    RESTRICTED
    Title: Retigabine, a KV7 (KCNQ) potassium channel opener, attenuates l-DOPA-induced dyskinesias in 6-OHDA-lesioned rats
    Journal Name: Neuropharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuropharm.2011.10.016
    Citation Count: 24
  • Summary Details
    RESTRICTED
    Title: What matters to people with Parkinson’s disease living in Australia?
    Journal Name: Journal of Clinical Neuroscience
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.jocn.2014.06.097
    Citation Count: 10
  • Summary Details
    OPEN
    Title: LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression
    Journal Name: Translational Neurodegeneration
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1186/s40035-024-00403-2
    Citation Count: 10
  • Summary Details
    OPEN
    Title: Data-Driven Sequence of Changes to Anatomical Brain Connectivity in Sporadic Alzheimer’s Disease
    Journal Name: Frontiers in Neurology
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fneur.2017.00580
    Citation Count: 49
  • Summary Details
    OPEN
    Title: Endoplasmic Reticulum Membrane Contact Sites, Lipid Transport, and Neurodegeneration
    Journal Name: Cold Spring Harbor Perspectives in Biology
    Publisher: Cold Spring Harbor Laboratory
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1101/cshperspect.a041257
    Citation Count: 35
  • Summary Details
    OPEN
    Title: UCP2 mediates ghrelin’s action on NPY/AgRP neurons by lowering free radicals
    Journal Name: Nature
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1038/nature07181
    Citation Count: 685
  • Summary Details
    OPEN
    Title: Pitx3 is required for development of substantia nigra dopaminergic neurons
    Journal Name: Proceedings of the National Academy of Sciences
    Publisher: Proceedings of the National Academy of Sciences
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1073/pnas.0230529100
    Citation Count: 382
  • Summary Details
    OPEN
    Title: Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson’s disease models
    Journal Name: Disease Models & Mechanisms
    Publisher: The Company of Biologists
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1242/dmm.004267
    Citation Count: 178
  • Summary Details
    OPEN
    Title: Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(18)30126-1
    Citation Count: 115
  • Summary Details
    OPEN
    Title: Assessing the relationship between monoallelic PRKN mutations and Parkinson’s risk
    Journal Name: Human Molecular Genetics
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1093/hmg/ddaa273
    Citation Count: 54
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.